Kymera Therapeutics

Company

Last mentioned: Feb 26, 2026

Stories mentioning Kymera Therapeutics 2

pharma Neutral

Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.

12 sources
market-trends Neutral

Mid-Cap Biotech Earnings: Specialized Platforms Outperform in Q4 2025

The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.

12 sources